Vernal Keratoconjunctivitis Pipeline Analysis & Clinical Trials, 2025, Delveinsight Ico Therapeutics, Vanda Pharmaceuticals, Sylentis, Allakos

(MENAFN- GetNews)


"Vernal keratoconjunctivitis Pipeline"DelveInsight's,“Vernal Keratoconjunctivitis – Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Vernal Keratoconjunctivitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that over 5 key companies are actively engaged in developing more than 5 therapies for the treatment of Vernal Keratoconjunctivitis (VKC).

Vernal keratoconjunctivitis Overview:

Vernal Keratoconjunctivitis (VKC) is a rare, chronic allergic eye disorder that can result in significant vision problems. It primarily affects children and young adults and is mediated by IgE and T cells, leading to persistent inflammation involving eosinophils, lymphocytes, and structural cells.

Management of VKC typically combines conservative measures with medications. Symptoms often emerge before age 10 and may include cobblestone-like bumps (papillae) on the upper eyelid, light sensitivity, redness, sticky mucus discharge, and involuntary blinking or eyelid spasms. Treatment aims to prevent flare-ups and alleviate symptoms, with strategies such as avoiding allergens, wearing dark sunglasses, staying indoors during high pollen periods, and using topical eye drops as first-line therapy.

Additional relief may be provided by cold compresses, artificial tears, ointments, and topical antihistamines. In moderate cases, non-steroidal anti-inflammatory drugs (NSAIDs) can be helpful, while topical steroids are reserved for severe cases due to the risk of glaucoma with prolonged use.

Download our report @

"Vernal keratoconjunctivitis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Vernal keratoconjunctivitis Therapeutics Market.

Key Takeaways from the Vernal keratoconjunctivitis Pipeline Report

• DelveInsight's Vernal Keratoconjunctivitis (VKC) pipeline report highlights an active landscape, with over 5 companies developing more than 5 potential therapies for VKC treatment.

• In recent developments, the U.S. FDA approved Verkazia (cyclosporine ophthalmic emulsion) 0.1% eye drops for treating this rare, recurrent allergic eye disorder in both children and adults. VKC is marked by severe ocular surface inflammation, causing symptoms such as intense itching, pain, and light sensitivity, and can lead to corneal ulcers and potential vision loss if left untreated.

• Key companies in the VKC space include iCo Therapeutics, Vanda Pharmaceuticals, Sylentis, Allakos, and others, all working to expand treatment options.

• Promising pipeline therapies include iCo-008 and additional candidates.

Vernal keratoconjunctivitis Pipeline Analysis

The Vernal keratoconjunctivitis pipeline insights report 2025, provides insights into:

• Provides comprehensive insights into key companies developing therapies in the Vernal keratoconjunctivitis Market.

• Categorizes Vernal keratoconjunctivitis therapeutic companies by development stage: early, mid, and late-stage.

• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

• Reviews emerging Vernal keratoconjunctivitis drugs under development based on:

  • Stage of development

  • Vernal keratoconjunctivitis Route of administration

  • Target receptor

  • Monotherapy vs. combination therapy

  • Vernal keratoconjunctivitis Mechanism of action

  • Molecular type

• Offers detailed analysis of:

  • Company-to-company and company-academia collaborations

  • Vernal keratoconjunctivitis Licensing agreements

  • Funding and investment activities supporting future Vernal keratoconjunctivitis market advancement.

Request for a sample report @

Vernal keratoconjunctivitis Emerging Drugs

• iCo-008: iCo Therapeutics

Bertilimumab is a fully human monoclonal antibody that selectively targets human eotaxin-1, inhibiting its activity. Encouraging results from preclinical studies prompted the launch of three clinical trials in the EU, involving 126 participants, including healthy volunteers and patients with a history of seasonal allergic rhinitis and conjunctivitis. These trials showed that bertilimumab is well-tolerated and safe when administered intravenously, intranasally, or topically to the eye. A Phase II clinical trial is currently being prepared to evaluate its use in patients with vernal keratoconjunctivitis and/or atopic keratoconjunctivitis, conditions affecting both the cornea and conjunctiva.

Vernal keratoconjunctivitis Companies

More than five key companies are actively developing therapies for Vernal Keratoconjunctivitis (VKC), with iCo Therapeutics advancing drug candidates in the late Phase II stage.

DelveInsight's report covers around 100+ products under different phases of Vernal keratoconjunctivitis clinical trials like

• Vernal keratoconjunctivitis Late stage Therapies (Phase III)

• Vernal keratoconjunctivitis Mid-stage Therapies (Phase II)

• Vernal keratoconjunctivitis Early-stage Therapies (Phase I)

• Vernal keratoconjunctivitis Pre-clinical and Vernal keratoconjunctivitis Discovery stage Therapies

• Vernal keratoconjunctivitis Discontinued & Inactive Therapies

Vernal keratoconjunctivitis pipeline report provides the Vernal keratoconjunctivitis therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Vernal keratoconjunctivitis Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Vernal keratoconjunctivitis Therapies and Key Vernal keratoconjunctivitis Companies: Vernal keratoconjunctivitis Clinical Trials and recent advancements

Vernal keratoconjunctivitis Pipeline Therapeutic Assessment

. Vernal keratoconjunctivitis Assessment by Product Type

. Vernal keratoconjunctivitis By Stage

. Vernal keratoconjunctivitis Assessment by Route of Administration

. Vernal keratoconjunctivitis Assessment by Molecule Type

Download Vernal keratoconjunctivitis Sample report to know in detail about the Vernal keratoconjunctivitis treatment market @ Vernal keratoconjunctivitis Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Vernal keratoconjunctivitis Current Treatment Patterns

4. Vernal keratoconjunctivitis - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Vernal keratoconjunctivitis Late-Stage Products (Phase-III)

7. Vernal keratoconjunctivitis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Vernal keratoconjunctivitis Discontinued Products

13. Vernal keratoconjunctivitis Product Profiles

14. Vernal keratoconjunctivitis Key Companies

15. Vernal keratoconjunctivitis Key Products

16. Dormant and Discontinued Products

17. Vernal keratoconjunctivitis Unmet Needs

18. Vernal keratoconjunctivitis Future Perspectives

19. Vernal keratoconjunctivitis Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Vernal keratoconjunctivitis Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN08092025003238003268ID1110033993